NEWS HIGHLIGHTSMedia Articles Related to Banzel (Rufinamide)
Increased Risk Of Seizures Faced By Current Cigarette Smokers
Source: Health News from Medical News Today [2009.11.19]
A recent study determined there is a significant risk of seizure for individuals who currently smoke cigarettes. Boston-based researchers from Brigham and Women's Hospital and Harvard Medical School also found that long-term, moderate intake of caffeine or alcohol does not increase the chance of having a seizure or developing epilepsy.
Improved Understanding Of Why Seizures Occur With Alcohol Withdrawal
Source: Epilepsy News From Medical News Today [2009.10.19]
Epileptic seizures are the most dramatic and prominent aspect of the "alcohol withdrawal syndrome" that occurs when a person abruptly stops a long-term or chronic drinking habit. Researchers have shown that the flow of calcium ions into brain cells via voltage-gated calcium channels plays an important role in the generation of alcohol withdrawal seizures, because blocking this flow suppresses these seizures.
Gene Mutation Linked to Fever-Induced Seizures
Source: MedicineNet Seizure Specialty [2009.09.21]
Title: Gene Mutation Linked to Fever-Induced Seizures
Category: Health News
Created: 9/18/2009 2:10:00 PM
Last Editorial Review: 9/21/2009
Febrile Seizures And Severe Epilepsy In Infants Traced To A Sodium Channel Gene Mutation
Source: Epilepsy News From Medical News Today [2009.09.20]
Mutations in the SCN9A sodium channel gene are a cause of febrile seizures and contribute to a severe form of epilepsy in infants 6 months and younger, report researchers from the University of Utah, University of Antwerp, and University of Washington.
Febrile Seizures
Source: MedicineNet Pediatric Epilepsy Surgery Specialty [2008.05.09]
Title: Febrile Seizures
Category: Diseases and Conditions
Created: 5/9/2008
Last Editorial Review: 5/9/2008
Published Studies Related to Banzel (Rufinamide)
Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. [2009.08]
PURPOSE: To evaluate efficacy and safety of adjunctive treatment with rufinamide 1600 mg twice daily in subjects aged > or = 16 years with refractory partial seizures. METHODS: This double-blind, placebo-controlled, randomized, parallel-group, multicenter trial included an 8-week baseline phase and a 13-week double-blind phase...
Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. [2008.05.20]
BACKGROUND: Lennox-Gastaut syndrome is a catastrophic pediatric epilepsy syndrome characterized by multiple types of treatment-resistant seizures and high rates of seizure-related injury. Current available treatments are inadequate, leaving patients with few treatment options and opportunities... CONCLUSIONS: Rufinamide was an effective and well-tolerated treatment for seizures associated with Lennox-Gastaut syndrome.
Rufinamide: a new anti-epileptic medication. [2007.08]
Rufinamide (1-[2,6-difluorobenzyl]-1H-1,2,3-triazole-4-carboxamide) is a new anti-epileptic drug with a novel triazole derivative structure... Rufinamide has shown promise as adjunctive treatment for Lennox-Gastaut syndrome and may have some role in localization related epilepsies as well.
Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy). [2007.02]
Rufinamide, a triazole derivative that is structurally distinct from currently marketed antiepileptic drugs (AEDs), is in development for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in children and adults. Rufinamide is well absorbed after oral administration, demonstrates low protein binding, and is metabolized by enzymatic hydrolysis without involvement of cytochrome P450 enzymes, conferring a low drug interaction potential...
Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide. [2009.04]
Lennox-Gaustaut syndrome is an electroclinical epilepsy syndrome characterized by the triad of electroencephalogram showing diffuse slow spike-and-wave discharges and paroxysmal fast activity, multiple intractable seizure types, and cognitive impairment.Our focus will be on the role of the new medication rufinamide in seizure reduction in patients with Lennox-Gaustaut syndrome.
|
